JAMA
Original Investigation
April 8, 2024
Steven E.ÌýNissen,ÌýMD; KathyÌýWolski,ÌýMPH; Gerald F.ÌýWatts,ÌýMD, DSc; Michael J.ÌýKoren,ÌýMD; HenryÌýFok,ÌýMBBS, PhD; Stephen J.ÌýNicholls,ÌýMBBS, PhD; David A.ÌýRider,ÌýPhD; LeslieÌýCho,ÌýMD; StevenÌýRomano,ÌýMD; CarrieÌýMelgaard,ÌýMS; CurtisÌýRambaran,ÌýMBBS, MD
JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.
JAMA
Preliminary Communication
April 3, 2022
Steven E.ÌýNissen,ÌýMD; KathyÌýWolski,ÌýMPH; CraigÌýBalog,ÌýBS; Daniel I.ÌýSwerdlow,ÌýMD, PhD; Alison C.ÌýScrimgeour,ÌýMSc; CurtisÌýRambaran,ÌýMD; Rosamund J.ÌýWilson,ÌýPhD; MalcomÌýBoyce,ÌýMD; Kausik K.ÌýRay,ÌýMD; LeslieÌýCho,ÌýMD; Gerald F.ÌýWatts,ÌýMD, PhD; MichaelÌýKoren,ÌýMD; TraciÌýTurner,ÌýMD; Erik S.ÌýStroes,ÌýMD, PhD; CarrieÌýMelgaard,ÌýMS; Giles V.ÌýCampion,ÌýMD, PhD
free access
has multimedia
JAMA. 2022; 327(17):1679-1687. 10.1001/jama.2022.5050
This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.